A Japanese health ministry proposal to impose steeper price cuts on certain medicines deemed to carry poor cost-effectiveness profiles cleared…
HOME > COMMENTARY
COMMENTARY
- COMMENTARY／Hisamitsu Aims at Growth by Fusing Its and Noven's Technologies
August 24, 2009
- COMMENTARY／Permitting MSs to Take MR Cert. Exam Offers New Business Opportunity to Wholesalers
August 3, 2009
- COMMENTARY／Fair Profits Are Essential to Spread Regenerative Medicine
August 3, 2009
- Hitech Drugs Open the Window to the Future- With Special Focus on Development and Marketing -(1)
July 20, 2009
- Hitech Drugs Open the Window to the Future- With Special Focus on Development and Marketing -(2)
July 20, 2009
- COMMENTARY／Global Pharmas Enhance Their Presence in Japan
July 13, 2009
- COMMENTARY／Additional Price Cuts for Long-listed Original Drugs
June 29, 2009
- COMMENTARY／Clinical Applications of ADCs Coming Closer to Reality
June 29, 2009
- SURVEY／RLS Takes Almost Four Years before Being Diagnosed
June 22, 2009
- COMMENTARY／JSHP to Promote Use of Generics
June 8, 2009
- COMMENTARY／Combination Drugs Becoming a "Boom"
June 1, 2009
- COMMENTARY／Clearer Criteria Needed for Patent Period Restoration
May 4, 2009
- COMMENTARY／Why Does the Use of Generics Not Increase?
April 27, 2009
- EMTs Allowed to Administer Epipen
April 27, 2009
- COMMENTARY／Medway Data Falsification to Make Blood Product Self-Sufficiency Difficult
April 20, 2009
- The First Round Results of GE Amlodipine (2)- Making No Surprise Moves Leads to Success -
April 6, 2009
- COMMENTARY／Worst Scenario Coming True due to Heated Competition among Wholesalers
March 23, 2009
- Unexpected Demand for ActHIB Causes Shortage of Supply
March 16, 2009
- COMMENTARY／Aggressive Overseas Investments Affect Business of Top-4 Pharmas
February 23, 2009
- COMMENTARY／National Consensus Needed to Balance Soaring Costs of New Drugs against Their Benefits
February 16, 2009
ページ
A Japanese drug pricing panel on November 11 discussed ways to respond to the US most-favored-nation (MFN) policy, with healthcare…
On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…